Molecular cytogenetics in diagnostics of genetic abnormalities in cervical carcinoma

Czech version

Authors: Petr Kuglík ^1,2; Anna Laštůvková ^1,2; Vladimíra Vallová ^1,2; Kateřina Kašíková ^1,2; Lucie Mouková ³
Authors‘ workplace: Ústav experimentální biologie, Přírodovědecká fakulta, Masarykova Univerzita, Brno, vedoucí pracoviště prof. RNDr. Jan Šmarda, CSc. ¹; Oddělení lékařské genetiky, Fakultní nemocnice, Brno, primářka prim. MUDr. Renata Gaillyová, Ph. D. ²; Oddělení gynekologické onkologie, Masarykův onkologický ústav, Brno, primář MUDr. Josef Chovanec, Ph. D. ³
Published in: Prakt Gyn 2013; 17(1): 53-57
Category: Oncogynecology: Original Article

Overview

The oncogynecological guideline of cervical cancer treatment is mainly based on conventional histopathological prognostic factors. According to available studies, it seems that genetic defects and specific chromosomal aberrations can cause gene expression deregulation and so play an important role in the origin and the development of cervical intraepithelial neoplasia and influence the progression to cervical cancer. Especially the amplification of the human telomerase gene hTERC (3q26) and protooncogene MYCC (8q24) are associated with the progression. This study reviews the recent knowledge of the chromosomal aberration role in cervical carcinoma development and describes the multicolor HPV-FISH technique as molecular cytogenetic technique that allows common identification of HPV infected cells and amplification of the hTERC a MYCC genes in premalignant cervical dysplasia and cervical cancer cytology specimens. The test results enable to determine which samples carry high risk HPV infection and chromosomal aberrations with potential to progression in invasive cervical carcinoma. Detection of these new genetic markers can contribute to individualized targeted treatment and clarify follow-up.

Key words:
diagnostics of genetic abnormalities – cervical carcinoma/cancer – cervical intraepithelial neoplasia –molecular cytogenetics – human telomerase gene hTERC (3q26) – protooncogene MYCC (8q24)

Sources

1. Barr E, Sings HL. Prophylactic HPV vaccines: New interventions for cancer kontrol. Vaccine 2008; 26(49): 6244–6257.

2. Freitag P. Rizikové a prognostické faktory gynekologických zhoubných nádorů. Moderní gynekologie a porodnictví 2007; 16(3 Onkogynekologie): 448–449.

3. Cibula D, Petruželka L et al. Nádory děložního hrdla. In: Cibula D, Petruželka L (eds) et al. Onkogynekologie. Grada Publishing, Praha 2009: 393–456.

4. Golijow CD, Abba MC, Mourón SA et al. c-myc gene amplification detected in preinvasive inraepithelial cervical lesions. Int J Gynecol Cancer 2001; 11(6): 462–465.

5. Heselmeyer K, Schrock E, du Manoir S et al. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci USA 1996; 93(1): 479–484.

6. Heselmeyer K, Macville M, Schrock E et al. Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. Genes Chromosomes Cancer 1997; 19(4): 233–240.

7. Jin Y, Li JP, He D et al. Clinical significance of human telomerase RNA gene (hTERC) amplification in cervical squamous cell lesions detected by fluorescence in situ hybridization. Asian Pac J Cancer Prev 2011; 12(5): 1167–1171.

8. Chen S, Yang Z, Zhang Y et al. Genomic amplification patterns of human telomerase RNA gene and C-MYC in liquid-based cytological specimens used for the detection of high-grade cervical intraepithelial neoplasia. Diagn Pathol 2012; 7: Art. no 40. Dostupný z WWW: <http://www.diagnosticpathology.org/content/7/1/40>.

9. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005; 6(8): 635–645.

10. Schwab M, Alitalo K, Klempnauer KH et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature 1983; 305(5931): 245–248.

11. Busmanis I. Biomarkers in Carcinoma of the Cervix: Emphasis on Tissue-related Factors and Their Potential Prognostic Factors. Ann Acad Med Singapore 1998; 27(5): 671–675.

12. Allen DG, White DJ, Hutchins AM et al. Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer. Br J Cancer 2000; 83(12): 1659–1663.

13. Oh EK, Kim YW, Kim IW et al. Differential DNA copy number aberrations in the progression of cervical lesions to invasive cervical carcinoma. Int J Oncol 2012; 41(6): 2038–2046.

14. Lee BH, Roh S, Kim YI. et al. Difference of Genome-Wide Copy Number Alterations between High-Grade Squamous Intraepithelial Lesions and Squamous Cell Carcinomas of the Uterine Cervix. Korean J Pathol 2012; 46(2): 123–130.